The Patent Finder

Kudos Pharmaceuticals Limited

16 patents currently held · Updated Nov 17, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

16
Ending by 2030
Aug 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 11, 2027
    The maintenance fee for Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors (US 9,102,670) comes due Feb 11, 2027. Unpaid by Aug 11, 2027, it lapses early.
  • 1 fee due Nov 7, 2027
    The maintenance fee for Immediate Release Pharmaceutical Formulation of 4-[3-(4-Cyclopropanecarbonyl-PIPERAZINE-1-Carbonyl)-4-Fluoro-BENZYL]-2H-PHTHALAZIN-1-ONE (US 11,975,001) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,071,579DNA damage repair inhibitors for the treatment of cancer
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,101,602Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,102,670Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,717,736Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,034,884Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,692,006Phthalazinone derivatives
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,143,241DNA damage repair inhibitors for treatment of cancer
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,449,464Phthalazinone derivatives
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,247,416Phthalazinone derivative
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,183,3694- [3- (4-Cyclopropanecarbonyl-PIPERAZINE-I-CARBONYL) -4 -Fluoro-Benzyl] -2H-PHTHALAZ IN-1-ONE
In force
 · High confidence
In forceHigh confidence
10 of 16 patents shown.
Pro members see all 16.
Pro members: see all 16 patents
Also on record, not counted in the 16: 1 patent in force now held by others · 18 lapsed for an unpaid fee · 9 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 abandoned · 16 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited